Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
11.32
-0.79 (-6.52%)
Jun 12, 2025, 4:00 PM - Market closed
Zenas BioPharma Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Zenas BioPharma stock ranges from a low of $19 to a high of $45. The average analyst price target of $32.29 forecasts a 185.25% increase in the stock price over the next year.
Price Target: $32.29 (+185.25%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Zenas BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 2 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +165.02% | May 16, 2025 |
| Wedbush | Wedbush | Buy Initiates $35 | Buy | Initiates | $35 | +209.19% | Mar 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +297.53% | Mar 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +165.02% | Mar 12, 2025 |
| Wolfe Research | Wolfe Research | Buy Initiates $19 | Buy | Initiates | $19 | +67.84% | Feb 4, 2025 |
Financial Forecast
Revenue This Year
15.30M
from 5.00M
Increased by 206.00%
Revenue Next Year
27.14M
from 15.30M
Increased by 77.40%
EPS This Year
-4.45
from -11.89
EPS Next Year
-4.37
from -4.45
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 26.3M | 89.3M | 147.3M |
| Avg | 15.3M | 27.1M | 59.7M |
| Low | 9.8M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 425.0% | 483.3% | 442.8% |
| Avg | 206.0% | 77.4% | 120.0% |
| Low | 96.0% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -3.98 | -3.81 | -3.72 |
| Avg | -4.45 | -4.37 | -4.02 |
| Low | -5.30 | -5.09 | -4.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.